Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Köln, Universität zu Köln, Dissertation, 2023
- Schlagwort
-
Maus
- Ereignis
-
Veröffentlichung
- (wo)
-
Köln
- (wer)
-
Universitäts- und Stadtbibliothek Köln
- (wann)
-
2023
- Urheber
-
Muinos-Buehl, A.
- Beteiligte Personen und Organisationen
-
Rugarli, Elena
Vilchez, David
- URN
-
urn:nbn:de:hbz:38-706731
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:45 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Muinos-Buehl, A.
- Rugarli, Elena
- Vilchez, David
- Universitäts- und Stadtbibliothek Köln
Entstanden
- 2023
Ähnliche Objekte (12)
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Pattern of pareses in 5q-spinal muscular atrophy
Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Diagnosis and management of spinal muscular atrophy : : Part 2
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
Costs of illness of spinal muscular atrophy: a systematic review
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Synthese und Anwendung Phosphatrückgrat-Modifizierter Antisense-Oligonucleotide gegen Hepatitis-C-Virus-RNA
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Pattern of pareses in 5q-spinal muscular atrophy
Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Diagnosis and management of spinal muscular atrophy : : Part 2
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
Costs of illness of spinal muscular atrophy: a systematic review
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Synthese und Anwendung Phosphatrückgrat-Modifizierter Antisense-Oligonucleotide gegen Hepatitis-C-Virus-RNA
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Pattern of pareses in 5q-spinal muscular atrophy
Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Diagnosis and management of spinal muscular atrophy : : Part 2
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
Costs of illness of spinal muscular atrophy: a systematic review
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy